Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04922645 · ClinicalTrials.gov registry record · Phase 4
Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants
A Phase 4 study, sponsored by USRC Kidney Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 214
- Enrollment target
NCT04922645: Completed Phase 4 study, sponsored by USRC Kidney Research.
NCT04922645 is a Phase 4 study that has completed, run by USRC Kidney Research. The registered enrollment target is 214 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04922645, a Phase 4 study, has completed, sponsored by USRC Kidney Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 214 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.
Primary Outcome
Difference in change from baseline period (Month -3 to Day 1) to months 4 to 6 (efficacy evaluation period) in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups.
Interventions
- DRUG Ferric Citrate 1 gram Oral Tablet
- DRUG Standard of care phosphate-lowering therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2022-09-15 |
| Phase | Phase 4 |
What the finished NCT04922645 record still lists
NCT04922645 is an interventional study that assigns participants to a tested intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Ferric Citrate 1 gram Oral Tablet is the first listed.
NCT04922645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04922645 about?
NCT04922645 is a clinical study titled "Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants". This study is being conducted to demonstrate the effect of Auryxia, when used as the primary phosphate lowering therapy, on the overall cumulative use of erythropoiesis-stimulating agent and intravenous iron as well as on the laboratory parameters indicative of phosphate and anemia management.
What is the current status of trial NCT04922645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2021-06-29. Estimated completion is 2022-09-15.
What interventions are being tested in trial NCT04922645?
The interventions under investigation include: Ferric Citrate 1 gram Oral Tablet (DRUG), Standard of care phosphate-lowering therapy (DRUG).
Who is sponsoring clinical trial NCT04922645?
This trial is sponsored by USRC Kidney Research, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04922645's enrollment target sits among peer trials
214 394th of 2000 higher than 1,605 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI